Welcome to our dedicated page for Balchem SEC filings (Ticker: BCPC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Balchem Corporation (NASDAQ: BCPC) files a range of documents with the U.S. Securities and Exchange Commission that provide detailed insight into its operations as a global specialty ingredient manufacturer. This SEC filings page aggregates those disclosures, including current reports on Form 8-K and, via EDGAR, the company’s annual reports on Form 10-K, quarterly reports on Form 10-Q and other required filings.
Recent Form 8-K filings show how Balchem uses current reports to furnish quarterly financial results. For example, the company has filed 8-Ks under Item 2.02, “Results of Operations and Financial Condition,” to attach press releases reporting net sales, segment earnings, adjusted EBITDA and free cash flow for its Human Nutrition & Health, Animal Nutrition & Health and Specialty Products segments. Another Form 8-K details the results of Balchem’s annual meeting of shareholders, including director elections, auditor ratification and advisory votes on executive compensation.
Through this page, users can access Balchem’s periodic reports, which typically include segment information, risk disclosures, accounting policies and other data relevant to its specialty ingredients, animal nutrition and specialty chemical activities. Filings related to governance matters, such as shareholder voting outcomes, are also available.
Stock Titan enhances these filings with AI-powered summaries that explain complex sections in plain language, highlight key segment trends and clarify items such as non-GAAP measures referenced in Balchem’s earnings releases. Real-time updates from EDGAR help users see new 10-K, 10-Q and 8-K filings as they are posted, while Form 4 and other ownership-related filings can be reviewed to monitor insider transactions. This combination of official documents and AI-assisted analysis allows investors and researchers to study Balchem’s regulatory history, financial reporting and governance practices in a structured and accessible way.
Backus William A., VP & Chief Accounting Officer of CORP (BCPC), reported a routine share withholding related to equity compensation. On 04/01/2025, 383 shares of common stock at $167.24 per share were withheld to cover taxes upon vesting of restricted shares granted on 4/1/2022.
After this transaction, he beneficially owned 5,839 common shares directly and 256 common shares indirectly through a 401(k) plan as of 4/1/2025. The report notes it was an inadvertent late filing caused by an administrative error.
An officer of the issuer with ticker BCPC, SVP and GM, Specialty Products Job Leonard van Gunsteren, reported a routine tax-related share withholding. On February 8, 2026, 258 shares of common stock were withheld at $173.16 per share to cover taxes due on the vesting of restricted shares granted on February 8, 2023.
After this withholding, van Gunsteren directly beneficially owns 9,188 shares of the company’s common stock. The transaction was coded “F,” indicating a tax withholding in connection with an equity award vesting rather than an open-market sale.
Balchem Corporation’s Chairman, President & CEO Theodore L. Harris reported a tax-related share withholding in company stock. On 02/08/2026, 3,225 shares of common stock were withheld at $173.16 per share to cover withholding taxes upon vesting of restricted shares granted on 2/8/2023.
Following this transaction, Harris directly beneficially owns 75,934 shares of common stock. In addition, 2,007 shares are held indirectly through a 401(k) Plan. A further 1,022.58 shares are held in a trust for the benefit of his mother, where he serves as trustee and disclaims beneficial ownership except for any pecuniary interest.
BCPC senior vice president Frederic Boned reported a small tax‑related share withholding tied to equity compensation. On February 8, 2026, 430 shares of common stock were withheld at $173.16 per share to cover taxes on restricted shares granted on February 8, 2023. After this transaction, Boned directly owned 5,215 common shares and indirectly held 441 shares through a 401(k) plan.
Corp SVP Chief Supply Chain Officer Martin Luther Reid reported an administrative share withholding tied to equity compensation. On 02/08/2026, 416 shares of common stock were withheld at $173.16 per share to cover taxes due on the vesting of restricted shares originally granted on 02/08/2023.
After this transaction, Reid beneficially owns 6,975 common shares directly and 542 common shares indirectly through a 401(k) plan. The filing reflects tax settlement related to stock-based compensation rather than an open-market sale.
BCPC executive Carl Martin Bengtsson, EVP & Chief Financial Officer, reported a routine tax-related share withholding. On February 8, 2026, 863 shares of common stock were withheld at $173.16 per share to cover taxes on vesting restricted shares granted on February 8, 2023.
After this transaction, Bengtsson beneficially owned 22,316 common shares directly and 1,086 common shares indirectly through a 401(k) plan. The filing reflects administrative settlement of equity compensation rather than an open-market sale.
Balchem Corporation SVP & Chief HR Officer Michael Brent Tignor reported a routine tax-related share withholding transaction. On 02/08/2026, 373 shares of common stock were withheld at a price of $173.16 per share to cover taxes due upon vesting of restricted shares granted on 02/08/2023.
After this withholding, Tignor beneficially owned 8,750 shares of common stock directly and 1,456 shares indirectly through a 401(k) plan. The filing reflects administrative equity compensation activity rather than an open-market sale.
Balchem (BCPC) officer Martin Luther Reid, SVP Chief Supply Chain Officer, reported an open‑market sale of 1,200 shares of common stock on 11/11/2025 at $154.44 per share. Following the transaction, he beneficially owns 7,391 shares directly and 532 shares indirectly via a 401(k) plan.
Balchem (BCPC) disclosed an insider Form 4 for SVP/GM, Human Nutrition & Health, reporting a Code F transaction on 10/31/2025. The filing shows 1,085 shares of common stock were withheld at $153.39 per share to cover taxes upon vesting of restricted shares granted on 10/31/2022.
Following the transaction, the officer beneficially owns 5,645 shares directly and 415 shares indirectly via a 401(k) plan.
Balchem Corp (BCPC) reported that its SVP and Chief R&D Officer acquired 2,500 shares of common stock on 10/20/2025 via a restricted stock grant at $0 per share. Following the transaction, the reporting person beneficially owns 2,500 shares, held directly.
The award vests ratably over three years—25% on the first anniversary, 25% on the second, and 50% on the third—subject to transfer restrictions under a Restricted Stock Grant Agreement.